@article{1e9b39afec36439c85fd818d08b89dfd,
title = "Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells (Cancer Immunology, Immunotherapy, (2018), 67, 2, (311-325), 10.1007/s00262-017-2073-0)",
abstract = "The authors would like to make the following corrections to the published article.Prior therapy for Patient 3 was high-dose IL-2, vemurafenib, ipilimumab, and dabrafenib (Table 1).TIL 1383I TCR complexes were tethered to the CM5 sensor surface and HLA-A2-tyrosinase complexes were injected over the surface (Methods and Fig. 5). The solution (3D) affinity of the TIL 1383I TCR was 13 μM (Fig. 5a and text).",
author = "Tamson Moore and Wagner, {Courtney Regan} and Scurti, {Gina M.} and Hutchens, {Kelli A.} and Constantine Godellas and Clark, {Ann Lau} and Kolawole, {Elizabeth Motunrayo} and Hellman, {Lance M.} and Singh, {Nishant K.} and Huyke, {Fernando A.} and Wang, {Siao Yi} and Calabrese, {Kelly M.} and Embree, {Heather D.} and Rimas Orentas and Keisuke Shirai and Emilia Dellacecca and Elizabeth Garrett-Mayer and Mingli Li and Eby, {Jonathan M.} and Stiff, {Patrick J.} and Evavold, {Brian D.} and Baker, {Brian M.} and {Le Poole}, {I. Caroline} and Boro Dropulic and Clark, {Joseph I.} and Nishimura, {Michael I.}",
note = "Publisher Copyright: {\textcopyright} 2017, Springer-Verlag GmbH Germany, part of Springer Nature.",
year = "2018",
month = feb,
day = "1",
doi = "10.1007/s00262-017-2102-z",
language = "English (US)",
volume = "67",
pages = "327",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",
}
